212 related articles for article (PubMed ID: 27109862)
1. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
[TBL] [Abstract][Full Text] [Related]
2. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.
Paiva B; Vídriales MB; Pérez JJ; López-Berges MC; García-Sanz R; Ocio EM; de Las Heras N; Cuello R; García de Coca A; Pardal E; Alonso J; Sierra M; Bárez A; Hernández J; Suárez L; Galende J; Mateos MV; San Miguel JF
Blood; 2011 Mar; 117(13):3613-6. PubMed ID: 21266717
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.
Muchtar E; Jevremovic D; Dispenzieri A; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Chakraborty R; Zeldenrust S; Kumar SK; Kyle RA; Rajkumar SV; Gertz MA
Blood; 2017 Jan; 129(1):82-87. PubMed ID: 27729322
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
Puig N; Paiva B; Lasa M; Burgos L; Perez JJ; Merino J; Moreno C; Vidriales MB; Toboso DG; Cedena MT; Ocio EM; Lecumberri R; García de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Pérez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Prosper F; Martinez-Lopez J; Lecrevisse Q; Verde J; Mateos MV; Lahuerta JJ; Orfao A; San Miguel JF
Leukemia; 2019 May; 33(5):1256-1267. PubMed ID: 30542145
[TBL] [Abstract][Full Text] [Related]
6. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
[TBL] [Abstract][Full Text] [Related]
7. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
Hu Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
[TBL] [Abstract][Full Text] [Related]
8. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.
Zhou P; Hoffman J; Landau H; Hassoun H; Iyer L; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):49-58. PubMed ID: 22100494
[TBL] [Abstract][Full Text] [Related]
9. AL amyloidosis with a localized B cell neoplasia.
Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
[TBL] [Abstract][Full Text] [Related]
10. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
Granzow M; Hegenbart U; Hinderhofer K; Hose D; Seckinger A; Bochtler T; Hemminki K; Goldschmidt H; Schönland SO; Jauch A
Haematologica; 2017 Jul; 102(7):1281-1290. PubMed ID: 28341732
[TBL] [Abstract][Full Text] [Related]
11. Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production.
Laeng RH; Altermatt HJ; Scheithauer BW; Zimmermann DR
Cancer; 1998 Jan; 82(2):362-74. PubMed ID: 9445195
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of miRNAs in AL amyloidosis.
Weng L; Spencer BH; SoohHoo PT; Connors LH; O'Hara CJ; Seldin DC
Amyloid; 2011 Sep; 18(3):128-35. PubMed ID: 21834602
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
15. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
16. A patient with AL amyloidosis with negative free light chain results.
Milani P; Valentini V; Ferraro G; Basset M; Russo F; Foli A; Palladini G; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):1035-7. PubMed ID: 26677890
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.
Paiva B; Martinez-Lopez J; Corchete LA; Sanchez-Vega B; Rapado I; Puig N; Barrio S; Sanchez ML; Alignani D; Lasa M; García de Coca A; Pardal E; Oriol A; Garcia ME; Escalante F; González-López TJ; Palomera L; Alonso J; Prosper F; Orfao A; Vidriales MB; Mateos MV; Lahuerta JJ; Gutierrez NC; San Miguel JF
Blood; 2016 Jun; 127(24):3035-9. PubMed ID: 27069257
[TBL] [Abstract][Full Text] [Related]
18. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
19. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
[TBL] [Abstract][Full Text] [Related]
20. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
Dittrich T; Bochtler T; Kimmich C; Becker N; Jauch A; Goldschmidt H; Ho AD; Hegenbart U; Schönland SO
Blood; 2017 Aug; 130(5):632-642. PubMed ID: 28550043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
